Israel’s InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) has entered into a binding agreement with famed boxer Mike Tyson’s cannabis brand Tyson 2.0 to distribute the latter company’s merchandise internationally.
InterCure announced the business partnership on Thursday and will be granted an exclusive license to cultivate, market and distribute Tyson 2.0 products throughout Israel, Switzerland, the United Kingdom, Germany and other countries in the European Union.
InterCure has also been granted a license to utilize the intellectual property and genetics of TYSON 2.0 for the purpose of cultivating and producing new products.
“My vision for TYSON 2.0 has been to share high-quality cannabis that has saved my life with my fans and people wherever they may be. This relationship with InterCure is the next step of scaling up our operations to deliver on that vision,” said Tyson.
InterCure says it is the fastest growing cannabis company outside of North America. Tyson also recently opened a cannabis cafe in the Netherlands’ capital Amsterdam.
An Undisputed Experience 🏆
Come @MikeTyson's new cafe in Amsterdam @coffeeshoptyson 🥊
Featuring the best cannabis brands in the world including @futureofrolling, @gpen, and @StundenglassInc 🔥 pic.twitter.com/wqfSrPHXUe
— TYSON 2.0 (@itstyson20) April 21, 2023
Read more: iAnthus opens Atlantic City’s first adult use dispensary
Read more: Ayr Wellness completes acquisition of Nevada’s Tahoe Hydroponics for US$1.5M
Hexo Corp. (TSX: HEXO) (NASDAQ: HEXO) partnered with Tyson 2.0 in August last year to produce and sell the boxer’s cannabis products in Canada.
Tyson 2.0 also collaborated with Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) and famed wrestler Ric Flair that month to launch the Ric Flair Drip Cannabis line throughout 11 American states.
In November 2022, Tyson’s company entered the Alaska market through a partnership with the CBD and THC producer Cold Creek Extracts to distribute vapes and “Mike Bites” edibles reminiscent of his famous clash with Evander Holyfield many years ago.
InterCure’s shares stayed flat at US$2.35 Friday on the Toronto Stock Exchange.